MacroGenics

Yahoo Finance • 7 months ago

Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday? (CORRECTED)

Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday? (CORRECTED) Editor’s note: This story has been updated to correct an error in the price a... Full story

Yahoo Finance • 11 months ago

Shareholders in MacroGenics (NASDAQ:MGNX) are in the red if they invested three years ago

It is a pleasure to report that the MacroGenics, Inc. (NASDAQ:MGNX) is up 74% in the last quarter. But that doesn't change the fact that the returns over the last three years have been disappointing. In that time, the share price dropped 6... Full story

Yahoo Finance • last year

MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results

Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of scheduleInitiated LORIKEET Phase 2 study of lorigerlimab Submitted IND for MGC026, a topoisomerase inhibitor-based ADC Conference call scheduled for today at 4:30 p.m. ET... Full story

Yahoo Finance • last year

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer,... Full story

Yahoo Finance • last year

MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program

ROCKVILLE, MD, Sept. 05, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer,... Full story

Yahoo Finance • 2 years ago

MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results

ZYNYZ™ is third product approved in U.S. that originated from MacroGenics' pipeline Multiple Phase 2 programs advancing in metastatic castration-resistant prostate cancer (mCRPC)Cash runway through 2025 with $270 million in non-dilutive fu... Full story

Yahoo Finance • 2 years ago

MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today... Full story

Yahoo Finance • 2 years ago

MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)

ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported... Full story

Yahoo Finance • 2 years ago

MacroGenics Provides Corporate Update and 2022 Financial Results

Cash runway extended through 2025 with $250 million in non-dilutive funding over past eight months TAMARACK study design modified with objective of accelerating data readoutEncouraging lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule)... Full story

Yahoo Finance • 2 years ago

MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million

ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, tod... Full story

Yahoo Finance • 2 years ago

MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call

ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, tod... Full story

Yahoo Finance • 2 years ago

MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium

Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved ≥ 90% PSA reduction (PSA90)Nine of 35 patien... Full story

Yahoo Finance • 2 years ago

MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference

ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced... Full story

Yahoo Finance • 2 years ago

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported... Full story

Yahoo Finance • 2 years ago

MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results

Collaboration with Gilead to develop bispecific antibodies, including MGD024, announced Planned initiation of Phase 2 portion of MGC018 TAMARACK study in prostate cancer by year-endAnticipated update on lorigerlimab (PD-1 × CTLA-4 bispecif... Full story

Yahoo Finance • 2 years ago

MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call

ROCKVILLE, MD, Oct. 26, 2022 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, toda... Full story

Yahoo Finance • 2 years ago

MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results

MacroGenics, Inc. First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignancies Plan to initiate MGC018 Phase 2/3 study in prostate cancer by year-end Initiates cost-saving measures through corporate restructur... Full story

Yahoo Finance • 2 years ago

MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call

ROCKVILLE, MD, July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today... Full story

Yahoo Finance • 2 years ago

MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer

ROCKVILLE, MD, July 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced th... Full story

Yahoo Finance • 2 years ago

MacroGenics to Participate in Upcoming Investor Conference

ROCKVILLE, MD, June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced... Full story